| Summary: | The aim of this present study was to comprehensively describe somatic DNA alterations and transcriptional alterations in the last extension of the HNSCC subsets in TCGA, encompassing a total of 528 tumours. In order to achieve this goal, transcriptional analysis, functional enrichment assays, survival analysis, somatic copy number alteration analysis and somatic alteration analysis were carried out. A total of 3491 deregulated genes were found in HNSCC patients, and the functional analysis carried out determined that tissue development and cell differentiation were the most relevant signalling pathways in upregulated and downregulated genes, respectively. Somatic copy number alteration analysis showed a “top five” altered HNSCC genes: CDKN2A (deleted in 32.03% of patients), CDKN2B (deleted in 28.34% of patients), PPFIA1 (amplified in 26.02% of patients), FADD (amplified in 25.63% of patients) and <i>ANO1</i> (amplified in 25.44% of patients). Somatic mutations analysis revealed <i>TP53</i> mutation in 72% of the tumour samples followed by <i>TTN</i> (39%), <i>FAT1</i> (23%) and <i>MUC16</i> (19%). Another interesting result is the mutual exclusivity pattern that was discovered between the <i>TP53</i> and <i>PIK3CA</i> mutations, and the co-occurrence of CDKN2A with the <i>TP53</i> and <i>FAT1</i> alterations. On analysis to relate differential expression genes and somatic copy number alterations, some genes were overexpressed and amplified, for example, FOXL2, but other deleted genes also showed overexpression, such as CDKN2A. Survival analysis revealed that overexpression of some oncogenes, such as EGFR, CDK6 or CDK4 were associated with poorer prognosis tumours. These new findings help us to develop new therapies and programs for the prevention of HNSCC.
|
|---|
